GlassScriptPhysician profile
Michael Richard Bann
NPI 1396203550
$2,884.33
in general payments reported to CMS, 2019-2025
18 companies · $2,884 in 2025
The $2,884 reported for 2025 was more than what 98% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $2,884.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,597 · Food and Beverage: $1,103 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,597.37 |
| Food and Beverage | $1,102.60 |
| Education | $184.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,923.13 | 2025 | Illumisite |
| Astrazeneca Pharmaceuticals LP | $147.36 | 2025 | Fasenra, Tezspire, Airsupra |
| Alexion Pharmaceuticals, INC. | $102.79 | 2025 | Soliris, Ultomiris |
| Glaxosmithkline, LLC. | $101.65 | 2025 | Nucala |
| Regeneron Healthcare Solutions, INC. | $101.11 | 2025 | Dupixent |
| Lilly USA, LLC | $89.98 | 2025 | Zepbound |
| Sanofi-Aventis U.S. LLC | $78.99 | 2025 | |
| Viatris Specialty LLC | $55.47 | 2025 | Yupelri |
| Axsome Therapeutics, INC. | $52.25 | 2025 | Sunosi |
| Merck Sharp & Dohme LLC | $46.35 | 2025 | Winrevair |
| Insmed, INC. | $32.71 | 2025 | Brinsupri, Arikayce |
| Philips North America LLC | $31.61 | 2025 | Vest Therapy Und |
| Genzyme Corporation | $25.52 | 2025 | |
| United Therapeutics Corporation | $22.31 | 2025 | Tyvaso |
| Grifols USA, LLC | $21.11 | 2025 | Prolastin-C Liquid |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $18.20 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Verona Pharma, INC. | $17.79 | 2025 | Ohtuvayre |
| Amgen INC. | $16.00 | 2025 | Tezspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.